Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Download

index.pdf

Date

2014-03-01

Author

Kiriş, Erkan
Burnett, JC
Soloveva, V
Kane, CD
Bavari, S

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

43
views

0
downloads

Botulinum neurotoxins (BoNTs) are exceptionally potent inhibitors of neurotransmission, causing muscle paralysis and respiratory failure associated with the disease botulism. Currently, no drugs are available to counter intracellular BoNT poisoning. To develop effective medical treatments, cell-based assays provide a valuable system to identify novel inhibitors in a time- and costefficient manner. Consequently, cell-based systems including immortalized cells, primary neurons, and stem-cell derived neurons have been established. Stem cell-derived neurons are highly sensitive to BoNT intoxication and represent an ideal model to study the biological effects of BoNTs. Robust immunoassays are used to quantify BoNT activity and play a central role during inhibitor screening. In this review, we examine recent progress in physiologically relevant cellbased assays and high-throughput screening approaches for the identification of both direct and indirect BoNT inhibitors.

Subject Keywords

Botulinum neurotoxin, Cell-based assays, Embryonic stem cells, Motor neurons, Drug discovery, High-throughput screening, High-content imaging, ELISA, MSD, Phenotypic screening

URI

https://hdl.handle.net/11511/38223

Journal

Expert review of molecular diagnostics

DOI

https://doi.org/10.1586/14737159.2014.867808

Collections

Department of Biology, Article

Suggestions

OpenMETU
Core

SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. Kiriş, Erkan; Nuss, JE; Wanner, LM; Peyser, BD; Du, HT; Gomba, GY; Kota, KP; Panchal, RG; Gussio, R; Kane, CD; Tessarollo, L; Bavari, S (2015-05-01) Botulinum neurotoxins (BoNTs), the causative agents of botulism, are potent inhibitors of neurotransmitter release from motor neurons. There are currently no drugs to treat BoNT intoxication after the onset of the disease symptoms. In this study, we explored how modulation of key host pathways affects the process of BoNT intoxication in human motor neurons, focusing on Src family kinase (SFK) signaling. Motor neurons derived from human embryonic stem (hES) cells were treated with a panel of SFK inhibitors a...
Investigation of docetaxel and doxorubicin resistance in mcf-7 breast carcinoma cell line Darcansoy İşeri, Özlem; Gündüz, Ufuk; Department of Biotechnology (2009) Multidrug resistance phenotype of tumor cells describes resistance to wide range of structurally unrelated anticancer agents and is a serious limitation to effective chemotherapy. It is a multifactor yet not fully elucidated phenomenon by the involvement of diverse cellular pathways. Aim of this study was to investigate the resistance mechanisms developed against docetaxel and doxorubicin that are widely used in the treatment of breast cancer in model cell line MCF-7. Resistant sublines were developed by ap...
Development of a novel zebrafish xenograft model in ache mutants using liver cancer cell lines Avci, M. Ender; Keskus, Ayse Gokce; Targen, Seniye; Isilak, M. Efe; Ozturk, Mehmet; Atalay, Rengül; ADAMS, MİCHELLE; KONU KARAKAYALI, ÖZLEN (2018-01-25) Acetylcholinesterase (AChE), an enzyme responsible for degradation of acetylcholine, has been identified as a prognostic marker in liver cancer. Although in vivo Ache tumorigenicity assays in mouse are present, no established liver cancer xenograft model in zebrafish using an ache mutant background exists. Herein, we developed an embryonic zebrafish xenograft model using epithelial (Hep3B) and mesenchymal (SKHep1) liver cancer cell lines in wild-type and achesb55 sibling mutant larvae after characterization...
Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency Sefer, Asena Pinar; et. al. (2022-01-01) Purpose MALT1 deficiency is a combined immune deficiency characterized by recurrent infections, eczema, chronic diarrhea, and failure to thrive. Clinical and immunological characterizations of the disease have not been previously reported in large cohorts. We sought to determine the clinical, immunological, genetic features, and the natural history of MALT-1 deficiency. Methods The clinical findings and treatment outcomes were evaluated in nine new MALT1-deficient patients. Peripheral lymphocyte subset anal...
Synthesis of poly (dl-lactic-co-glycolic acid) coated magnetic nanoparticles for anti-cancer drug delivery Tansık, Gülistan; Gündüz, Ufuk; Department of Biology (2012) One of the main problems of current cancer chemotherapy is the lack of selectivity of anti-cancer drugs to tumor cells which leads to systemic toxicity and adverse side effects. In order to overcome these limitations, researches on controlled drug delivery systems have gained much attention. Nanoscale based drug delivery systems provide tumor targeting. Among many types of nanocarriers, superparamagnetic nanoparticles with their biocompatible polymer coatings can be targeted to an intented site by an extern...

Citation Formats

E. Kiriş, J. Burnett, V. Soloveva, C. Kane, and S. Bavari, “Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.,” Expert review of molecular diagnostics, pp. 153–68, 2014, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/38223.